(Reuters) - The company, which makes an array of prescription drugs, medical devices and diagnostics, also told analysts in a conference call that it expects a full-year tax rate of 19.5 percent.
It said the tax rate had been 20 percent in the first and second quarters.
Read more at Reuters.com Hot Stocks News
It said the tax rate had been 20 percent in the first and second quarters.
Read more at Reuters.com Hot Stocks News
No comments:
Post a Comment